Inventiva FY23 conference call feedback
In this note we provide a summary of the feedback from Inventiva's FY23 conference call. The company's CEO provided an overview of Inventiva's progress in 2023 and early 2024. This was followed by Q&A which largely focussed on the resumption of recruitment in the phase 3 (NATiV3) trial with lanifibranor in MASH, strength of the lanifibranor dataset vs. competitors, as well as partnering and funding options to reach NATiV3 topline readout expected in 1H26. Read our morning note on Inventiva's FY23 results HERE.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.